This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

XELIRI

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What XELIRI Means in Everyday Medical Language

XELIRI is a name for a chemotherapy treatment that combines two drugs: capecitabine (often called Xeloda) and irinotecan hydrochloride. Capecitabine is a pill taken by mouth that changes into an active chemotherapy drug inside the body, while irinotecan is given through a vein as an infusion. Together, these drugs attack cancer cells in different ways, which can help improve the chances of controlling the cancer. This treatment is mainly used for colorectal cancer that has spread beyond the colon or rectum, as well as for advanced esophageal (throat) and stomach cancers.

Why XELIRI Can Matter in Cancer Care

Cancers that have spread (metastasized) often require stronger or more complex treatments than cancers caught early. Using a combination like XELIRI can sometimes be more effective than a single drug alone because the two drugs work differently to kill cancer cells. This combination may help slow cancer growth, relieve symptoms, and improve quality of life. While XELIRI is not a cure by itself, it is an important option in managing advanced cancers that are difficult to treat. Doctors may include this regimen as part of a broader treatment plan depending on the patient’s cancer type, stage, and overall health.

What Patients Might See, Hear, or Be Told About XELIRI

You might hear your healthcare team mention XELIRI, CAPIRI, CAPIRI regimen, or XELIRI regimen. These all refer to the same combination of capecitabine and irinotecan. Your doctor or nurse will explain how this treatment fits your specific cancer type and stage, what side effects to expect, and how the drugs are given. Capecitabine is taken as a pill, while irinotecan is given by infusion, so you may experience different side effects from each drug. Your care team will monitor you closely and help manage any symptoms that arise.

Where the Term XELIRI Might Appear

The term XELIRI or its other names may appear in your treatment plan, medical records, drug information pages, or discussions about chemotherapy options. It can also be mentioned in clinical trial information comparing different treatments. Knowing that XELIRI is one of several chemotherapy regimens helps you understand your options and ask informed questions.

What XELIRI Does Not Automatically Mean

Hearing the term XELIRI does not mean your cancer is at a certain stage or that you will definitely receive this treatment. It is one option among many, and doctors decide based on your cancer type, how far it has spread, your overall health, and other factors. XELIRI is not a test or diagnosis but a treatment approach aimed at managing advanced cancer.

Common Questions to Ask Your Care Team

It can be helpful to ask why XELIRI is recommended for your cancer, what side effects you might expect, how the treatment schedule works, and how your response to treatment will be monitored. You might also ask how XELIRI compares to other chemotherapy options and what support is available to manage side effects.

How to Read the Term in Context

Because XELIRI is sometimes called CAPIRI or CAPIRI regimen, comparing the wording in a report or source can help avoid confusion. The important point is to read XELIRI in context and ask your care team how it applies to your specific situation, rather than treating the word alone as a diagnosis or treatment recommendation.

Safety and Next Steps

This information is meant to educate and does not decide what is safe or appropriate for any individual patient. If you see the term XELIRI in your medical records or hear it during your care, the safest next step is to ask your healthcare team what it means for you personally. They can explain how this treatment fits into your overall care and what to expect.

Sources

Public source information used for this glossary entry includes: